Solasta Ventures

Congrats to the EvolveImmune team!

FNAIT is officially on notice 📣 today, as we’ve announced the CTA approval of our lead program, RLYB212, to move into a Phase 2 trial in pregnant women at higher risk of alloimmunization and FNAIT.    Fetal and neonatal alloimmune thrombocytopenia (FNAIT) is a rare immune disorder in which a mother's body develops an antigen response against her baby's platelets and can cause uncontrolled bleeding or death in mothers, fetuses and newborns.     More than 30,000 pregnancies are at risk every year, and this trial is the next step in advancing RLYB212 aimed at preventing maternal alloimmunization and FNAIT.    Learn more about what's coming up next and how we're working towards the prevention of this #raredisease for pregnant women everywhere:

We’re proud to support a stellar team, focused on developing promising medicines in epilepsy and other neurological disorders. Very excited to be part of this compelling story.

Are you a scientist with interesting data for a potential therapy or a platform to develop novel therapies? Are you an entrepreneur seeking feedback on your pitch deck ahead of fundraising? Are you somewhere in between? If you answered yes to any of these, we'd love to meet with you through our Solasta Hatchery program! The Hatchery allows you to meet (virtually or in-person) with our team of biotech investors in a casual, office-hours/AMA environment to solicit general feedback or discuss data sets and future experiments, strategy, pitch deck feedback - whatever may be helpful for your next steps. Submit information through our quick intake form here: https://lnkd.in/dcGJvMDV and the Solasta team will be in touch from there.

Congrats to our portfolio company, ReCode Therapeutics, with their recent collaboration with Intellia. We're excited by the positive impact this will hopefully have in patients with Cystic Fibrosis.